Addiction and Substance Use Disorders
Addiction is a complex, multifaceted disorder that affects individuals both physically and mentally. Whether it's substance abuse or behavioral addictions, understanding the underlying causes and effective treatments is crucial. The Journal of Clinical Psychiatry offers comprehensive insights into addiction, from the latest research findings to evidence-based treatment approaches. Our expert editors curate content that sheds light on the intricacies of addiction, ensuring psychiatrists are equipped to offer holistic and effective care to those struggling with this challenging condition.
The Weekly Mind Reader: Semaglutide In Alcohol Use Disorder Treatment
Semaglutide, known for its effectiveness in obesity treatment, shows promise in reducing symptoms of alcohol use disorder.
Vinegar-Induced Disulfiram Reaction
A patient on disulfiram treatment developed erythematous plaques and papules after consumption of noodles containing vinegar.
Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series
Six patients who screened positive for alcohol use disorder (AUD) received semaglutide for weight loss. All subsequently showed significant improvement in AUD symptoms.
Recent JCP Articles
Longitudinal Description and Prediction of Smoking Among Borderline Patients: An 18-Year Follow-Up Study
This study assessed predictors of smoking in borderline personality disorder and compared smoking prevalence in recovered vs non-recovered patients.
Alcohol Use Disorder Treatment in Sexually and Gender Diverse Patients: A Retrospective Cohort Study
Sexually and gender diverse (SGD) patients had significantly higher rates of both AUD diagnosis and care utilization compared with non-SGD patients.
Emerging Perspectives in Addiction Psychiatry
FDA-approved medications and early intervention for people with substance use disorders should be encouraged as early as possible to optimize patient outcomes and life expectancy.
Recent PCC Articles
“Poor Person’s Cocaine”: Bupropion Insufflation Inducing Manic Symptoms and Its Abuse Potential in Dual Diagnosis Patients
Bupropion is considered a substance of low abuse potential. This report describes a case of bupropion misuse leading to mania in a patient with attention-deficit/hyperactivity disorder.
The Role of Non-Pharmaceutical Fentanyl–Contaminated Counterfeit Oxycodone in Increasing Opioid Overdoses: A Commentary Review
The growing use of fentanyl-contaminated products is fueling the US opioid crisis. This study reviewed the rising prevalence of nonprescription fentanyl in counterfeit oxycodone, paying specific attention to oxycodone for cost analysis.
The Appearance of Xylazine in the United States as a Fentanyl Adulterant
Data obtained from studies between 2006 and 2022 indicate a rapidly increasing incidence of xylazine overdose in the United States, with overdose cases now being seen in 25 states.
Front of Mind News
The Weekly Mind Reader: WHO Updates Key Mental Health Guidelines
The updated WHO mhGAP guideline offers vital recommendations for treating mental and neurological disorders.
Facebook, Instagram Sued by 33 States Over Harm to Youth Mental Health
Dozens of states filed a lawsuit against Meta, asserting that their social media apps damage the mental health of teens and children.
How Brain Networks in Recovered Psychosis Patients May Help Predict Relapse
An investigation into brain network biomarkers in psychosis patients could help predict relapse and guide treatment strategies.
7 Lifestyle Habits Cut Risk of Depression by 57 Percent, Study Finds
A new study reveals that a healthy lifestyle, including moderate drinking, better sleep and regular exercise can slash depression risk.
3 Key Updates on Psychopharmacology Drugs in the U.S.
The latest on OTC availability of Naloxone, the deadly drug Xylazine, and a clarification on state marijuana and federal gun laws.